Xenetic Biosciences IncXBIO
Price$2.32Intrinsic value$4.5596% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $3.3M+30.4% YoYTTM through 30 Jun 2026
Net Income -$2.5MTTM through 30 Jun 2026
Free Cash Flow -$2.3MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-79.9%
Operating Margin-62.2%
Net Margin-75.9%

Returns

-32.2%ROE
-28.3%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio7.93x
Net Debt-$7.3Mnet cash position
Cash & Equivalents$6.5M

Quality Metrics

Altman Z-Score-36.19
Piotroski F-Score3 / 9
FCF Margin-70.9%
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $3M
Diluted EPS-$1.15TTM
'21'22'23'24'25
FY2025: $-1.58

Dividend

No dividend

Capital Allocation

R&D Spend$2.7M
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.